Abstract
Acute myeloid leukemia (AML) is the most common subtype of leukemia in adult. Standard combined chemotherapy and hematopoietic stem cell transplantation (HSCT) are the major treatment of AML. In recent years, advances in molecular biology area, such as the completion of the human genome project, and next-generation sequencing, have brought new direction to anti-AML drugs, such as FMS-like tyrosine kinase (FLT) inhibitor, isocitrate dehydrogenase (IDH) 1/2 inhibitor, histone deacetylase (HDAC) inhibitor, epigenetic drugs, novel chemotherapeutic drug CPX-351, as well as CD33 antibody as the representative of antibody immunotherapy and chimeric antigen receptor T cell (CAR-T) immunotherapy. In this brief review, we presents an overview of novel agents currently in clinical trials that have data published or be hopeful to be used in clinic in treatment of AML. Key words: Leukemia, myeloid, acute; Drugs, investigational; Fms-Like tyrosine kinase 3; Isocitrate dehydrogenase; Histone deacetylase inhibitors; Immunotherapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
